Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Amgen today and set a price target of $307.00. Ahmad covers the Healthcare sector, focusing on stocks such as ACADIA ...
Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over ...
Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to ...
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $432.00. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful in ...
How Amgen’s Recent Share Performance Frames the Story Amgen (AMGN) has drawn attention after recent share price weakness, ...
US biotech major Amgen late yesterday announced financial results for the first quarter of 2026, showing that revenues ...
Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...
Amgen shares have risen 6% since the beginning of the year, while the S&P's 500 index has risen slightly more than 5%. In the final minutes of trading on Thursday, shares hit $347.44, a rise of 19% in ...
The biotechnology company posted adjusted earnings per share of $5.15, beating the analyst consensus of $4.80 by $0.35. Revenue reached $8.62 billion, slightly above the $8.59 billion estimate and up ...
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of ...
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of ...
Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results